33
/it/
AIzaSyB4mHJ5NPEv-XzF7P6NDYXjlkCWaeKw5bc
November 30, 2025
Create a timeline
Public Timelines
For education
For educational institutions
For teachers
For students
Cabinet
For educational institutions
For teachers
For students
Open cabinet
FAQ
Close
Create a timeline
Public timelines
FAQ
About & Feedback
Accordo
Privatezza
FAQ
Support 24/7
Cabinet
Get premium
Donate
Modificare
Scaricare
Export
Creare una copia
Premium
Integrare nel sito Web
Share
112017
Category:
Altro
è stato aggiornato:
15 nov 2017
new approvals in solid tumors
0
0
453
Autori
Created by
Paweł Potocki
Attachments
Comments
Eventi
Imatynib
Gefitynib
Erlotynib
Sorafenib
Sunitynib Dasatynib
Lapatynib Nilotynib
Pazopanib
wemurafenib kryzotynib ruksolitynib
aflibercept aksytynib enzalutamid ewerolimus kabozantynib pertuzumab regorafenib
afatatynib dabrafenib denosumab ibrutynib trametynib trastuzumab-emtanzyna rad-223
alektynib lenwatynib kobimetynib osimertynib palbocyklib sonidegib
ceritinib niwolumab olaparyb pembrolizumab ramucyrumab
atezolizumab rukaparyb olaratumab
abemacyklib awelumab brygantynib niraparyb neratynib rybocyklib
About & Feedback
Accordo
Privatezza
FAQ
Support 24/7
Cabinet
Get premium
Donate
The service accepts bank transfer (ACH, Wire) or cards (Visa, MasterCard, etc). Processed by Stripe.
Secured with SSL
Comments